MedTrace Logo

Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer

NCT01527864 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2012-02-07

No results posted yet for this study

Summary

A phase II, multicenter, randomized, double-blind, placebo-controlled study was carried out. Patients were randomly assigned to the treatment (PC + pegylated endostatin) or the control group (PC+ placebo). The efficacy was evaluated every six weeks.Follow-up continued until disease progression or death.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

pegylated endostatin and Paclitaxel-Carboplatin

Dosage：10mg/m2

DRUG

Placebo and Paclitaxel-Carboplatin

Dosage：10mg/m2

Sponsors & Collaborators

  • Protgen Ltd

    lead INDUSTRY

Principal Investigators

  • Yan Sun, MD · Cancer Hospital Chinese Academy of Medical Science

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-12-31
Completion
2013-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01527864 on ClinicalTrials.gov